Prothena Corporation plc

NASDAQ:PRTA

Biotechnology

Healthcare
$8.35 +3.89%

+$0.33 today

Market cap
$428.77M
Beta
-0.32
P/E (TTM)
-3.1
EPS (TTM)
-$2.81
52W Low $5.64High $11.80

Volume 0.76M

Average 0.51M

PRTA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Prothena Corporation plcNASDAQ: PRTA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $6.95M (cash outflow) rose 14370.8% year over year, ahead of the -1150.0% change in trailing-twelve-month financing cash flow.

Context

  • Financing cash flow amounted to 1.4% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Financing cash flow increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14370.8% holds above the trailing-twelve-month pace of -1150.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.95M-338829.7% QoQ
Last fiscal yearDec 2025
-$139K-108.9% YoY
LTMMar 2026
-$7.03M-1150.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14370.8%——
1 year-108.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(139K) USD
Year-over-year change
-108.9%

Financing Cash Flow vs competitors

How PRTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1150.0% is the lowest of 10, against a peer median of +256.9%.
  • Financing cash flow amounts to 12.1% of revenue for PRTA, versus a peer median of 28.5%.
PRTA Competitors
Financing Cash Flow for PRTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIIBBiogen Inc.LTM Jun 2026$1.04B USD+3214.4%-44.4%10.5%
DNLIDenali Therapeutics Inc.LTM Jun 2026$425.38M USD+1810.7%-15.2%11803.1%
ANNXAnnexon, Inc.LTM Mar 2026$141.69M USD+10.0%-4.0%—
PMNProMIS Neurosciences, Inc.LTM Jun 2026$91.07M USD+234.5%+33.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$87.96M USD+345.2%-12.7%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$45.05M USD+256.9%-23.8%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$35.74M USD+16725.1%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M USD+172.3%+87.5%—
PRTAProthena Corporation plcLTM Mar 2026$7.03M USD-1150.0%—12.1%
ACIUAC Immune S.A.LTM Dec 2025CHF 1.02M CHF-9.0%-10.2%28.5%
Peer median (excluding PRTA) —+256.9%-11.4%28.5%

Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income66.98M(116.95M)(147.03M)(122.31M)(244.09M)
Depreciation & Amortization1.12M744K928K893K895K
Deferred Income Tax4.57M(11.13M)(15.69M)(9.35M)43.24M
Stock-Based Compensation24.66M31.32M40.91M45.96M37.64M
Change in Working Capital(10.4M)(18.8M)(20.53M)(67.94M)(4.17M)
Accounts Receivables15K0(5.16M)5.16M0
Inventory00(8.9M)00
Accounts Payables(492K)11.87M22.86M(18.3M)(15.78M)
Other Working Capital(9.93M)(30.67M)(29.33M)(54.8M)11.6M
Other Non-Cash Items5.69M6M7.5M2.69M2.91M
Operating Cash Flow92.61M(108.82M)(133.91M)(150.05M)(163.58M)
Capital Expenditures(575K)(464K)(2.81M)(298K)(138K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0037K00
Investing Cash Flow(575K)(464K)(2.77M)(298K)(138K)
Debt Repayment00000
Common Stock Issued174.79M223.62M23.58M0(139K)
Common Stock Repurchased000(353K)0
Dividends Paid00000
Other Financing Activities15.54M17.84M21.52M1.91M0
Financing Cash Flow190.33M241.46M45.1M1.55M(139K)
Effect of Forex Changes00000
Net Change in Cash282.36M132.17M(91.58M)(148.79M)(163.86M)
Free Cash Flow92.03M(109.29M)(136.72M)(150.35M)(163.72M)

Prothena Corporation plc

NASDAQ:PRTA

Intrinsic Alpha fair value

Locked

Current Price

$8.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.